Home » Newsletters » BioWorld

BioWorld

Jan. 15, 1993

View Archived Issues

FDA APPROVES ARGUS TRIALS

CIBUS TAKES REVERSE APPROACH

B7 GENE PRODUCT PRIMES KILLER T CELLS

SEC APPROVES APPLIED BIO MERGER

SCIOS NOVA SELLS RECEPTOR SCREENING BUSINESS

DELIVERING NERVE GROWTH FACTOR TO BRAIN

SANDOZ INVESTS $75M IN NEUROSCIENCES INSTITUTE

RAC OKS 'COMPASSIONATE' USE OF GENE THERAPY

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Sex differences shape gene activity across the human brain
BioWorld
Genes that are switched on or off in the human brain differ between men and women. Moreover, these differences are not uniform. They vary across cortical regions...
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
Gilead Sciences patents new GTPase KRAS G12D inhibitors
BioWorld Science
Gilead Sciences Inc. has disclosed new GTPase KRAS G12D mutant inhibitors potentially useful for the treatment of cancer.